Dr. Mark A. Goldberg is a senior life science executive and innovator. Since 2018, he has served as Chairman and CEO of Allucent. In this capacity, Goldberg is responsible for overall strategy and day-to-day operations of the business. Prior to his current role, Goldberg served as President and Chief Operating Officer at Parexel International, where he led one of the world’s largest biopharmaceutical services companies. Goldberg was a key player on Parexel’s executive management team for more than 20 years and served as President and COO for 10 years. He was instrumental in driving business results through the application of his combined medical, technical, and clinical research expertise. He oversaw the geographic expansion of Parexel’s clinical development capabilities, including the extension of capabilities in the Asia-Pacific region. Before taking on the COO role, Goldberg served as President of Clinical Research Services, driving strong growth and performance in the company’s largest business segment. Prior to that, he served as President of Perceptive Informatics (now Calyx), helping to build Parexel’s leadership position in providing eClinical solutions that accelerate drug development. Before joining Parexel, Goldberg served as President and Director of WorldCare, Inc. (which he helped found), a telehealth spin-off from Massachusetts General Hospital (MGH). Goldberg holds a degree in computer science and engineering from the Massachusetts Institute of Technology and an M.D. from the University of Massachusetts Medical School. He completed residency training in diagnostic radiology at MGH, where he served as Chief Resident, as well as Staff Radiologist. Goldberg serves on the board of directors of Intensity Therapeutics, Inc.